Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DR. DATSONS LABS Mar-14 |
ACTAVIS Dec-18 |
DR. DATSONS LABS/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 126 | 14,478 | - | |
Low | Rs | 31 | 9,712 | - | |
Sales per share (Unadj.) | Rs | 133.0 | 3,551.4 | - | |
Earnings per share (Unadj.) | Rs | 0.2 | -1,143.9 | - | |
Cash flow per share (Unadj.) | Rs | 6.6 | 374.2 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Dividend yield (eoy) | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 128.8 | 14,647.7 | - | |
Shares outstanding (eoy) | m | 31.66 | 332.60 | - | |
Bonus/Rights/Conversions | FCCB | - | - | ||
Price / Sales ratio | x | 0.6 | 3.4 | 17.3% | |
Avg P/E ratio | x | 516.1 | -10.6 | -4,881.4% | |
P/CF ratio (eoy) | x | 11.8 | 32.3 | 36.6% | |
Price / Book Value ratio | x | 0.6 | 0.8 | 73.6% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 2,477 | 4,022,682 | 0.1% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 56 | 0 | - | |
Avg. sales/employee | Rs Th | NM | 69,892.5 | - | |
Avg. wages/employee | Rs Th | NM | 0 | - | |
Avg. net profit/employee | Rs Th | NM | -22,512.4 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,211 | 1,181,183 | 0.4% | |
Other income | Rs m | 79 | 22,588 | 0.3% | |
Total revenues | Rs m | 4,289 | 1,203,771 | 0.4% | |
Gross profit | Rs m | 569 | 30,953 | 1.8% | |
Depreciation | Rs m | 204 | 504,930 | 0.0% | |
Interest | Rs m | 430 | 68,161 | 0.6% | |
Profit before tax | Rs m | 13 | -519,550 | -0.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | -2 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 132,506 | 0.0% | |
Tax | Rs m | 6 | -6,584 | -0.1% | |
Profit after tax | Rs m | 5 | -380,460 | -0.0% | |
Gross profit margin | % | 13.5 | 2.6 | 515.3% | |
Effective tax rate | % | 48.0 | 1.3 | 3,790.1% | |
Net profit margin | % | 0.1 | -32.2 | -0.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 6,852 | 484,460 | 1.4% | |
Current liabilities | Rs m | 6,711 | 428,569 | 1.6% | |
Net working cap to sales | % | 3.3 | 4.7 | 70.8% | |
Current ratio | x | 1.0 | 1.1 | 90.3% | |
Inventory Days | Days | 161 | 20 | 821.3% | |
Debtors Days | Days | 318 | 66 | 480.3% | |
Net fixed assets | Rs m | 3,673 | 133,703 | 2.7% | |
Share capital | Rs m | 317 | 0 | - | |
Net worth | Rs m | 4,078 | 4,871,829 | 0.1% | |
Long term debt | Rs m | 1,671 | 1,715,548 | 0.1% | |
Total assets | Rs m | 12,633 | 7,615,778 | 0.2% | |
Interest coverage | x | 1.0 | -6.6 | -15.5% | |
Debt to equity ratio | x | 0.4 | 0.4 | 116.4% | |
Sales to assets ratio | x | 0.3 | 0.2 | 214.9% | |
Return on assets | % | 3.4 | -4.1 | -84.0% | |
Return on equity | % | 0.1 | -7.8 | -1.5% | |
Return on capital | % | 7.7 | -4.8 | -158.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,345 | 421,992 | 0.3% | |
From Investments | Rs m | -2,256 | 231,830 | -1.0% | |
From Financial Activity | Rs m | -1,200 | -724,265 | 0.2% | |
Net Cashflow | Rs m | -2,111 | -70,091 | 3.0% |
Compare DR. DATSONS LABS With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare DR. DATSONS LABS With: STRIDES PHARMA SCIENCE LUPIN FULFORD INDIA NOVARTIS SUVEN LIFE SCIENCES
Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 74 points, up 0.2% at 48,877 levels.
Should you bet on this gaming company backed by ace investor Rakesh Jhunjhunwala?
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.
More